Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736468 | 0.97 | HRH3 (0.53) | SLC6A2SLC6A4SIGMAR1HRH3KCNH2 | |
| SCHEMBL5736283 | 0.88 | MEN1 (0.61) | SLC6A2SLC6A4HRH3KCNH2MCHR1 | |
| SCHEMBL5738313 | 0.88 | MCHR1 (0.57) | SLC6A2SLC6A4SIGMAR1HRH3KCNH2 | |
| SCHEMBL5737258 | 0.87 | HRH3 (0.62) | SLC6A2SLC6A4HRH3KCNH2MCHR1 | |
| SCHEMBL5737766 | 0.86 | HRH3 (0.64) | SLC6A2SLC6A4HRH3KCNH2MCHR1 | |
| SCHEMBL5737099 | 0.86 | HRH3 (0.64) | SLC6A2SLC6A4HRH3KCNH2MCHR1 | |
| SCHEMBL5737022 | 0.85 | SLC6A2 (0.57) | SLC6A2SLC6A4HRH3KCNH2MCHR1 | |
| SCHEMBL5734336 | 0.85 | MCHR1 (0.61) | SLC6A2SLC6A4SIGMAR1HRH3KCNH2 | |
| SCHEMBL5737288 | 0.85 | MCHR1 (0.58) | SLC6A2SLC6A4SIGMAR1HRH3KCNH2 | |
| SCHEMBL5737519 | 0.84 | MCHR1 (0.60) | SLC6A2SLC6A4SIGMAR1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349833-B1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1349833-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002044149-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | SLC6A2 529/4885SLC6A4 989/4885SIGMAR1 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.